<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317612</url>
  </required_header>
  <id_info>
    <org_study_id>Mindberry2020</org_study_id>
    <nct_id>NCT04317612</nct_id>
  </id_info>
  <brief_title>Effect of Nordic Berries on Cognitive Function, Cardiometabolic Risk Markers and Gut Microbiota in Adults With Mild Cognitive Impairment</brief_title>
  <acronym>MINDBERRY</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Intervention Study to Evaluate the Effect of Nordic Berries on Cognitive Function, Cardiometabolic Risk Markers and Gut Microbiome in Adults With Mild Cognitive Impairment The MINDBERRY Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to investigate whether daily intake of Nordic berries for 12&#xD;
      weeks can improve cognitive abilities of adults with mild cognitive impairment, and whether&#xD;
      the effect can be linked to changes in metabolic parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted with a randomized, double-blind, parallel-group (2 arms)&#xD;
      placebo-controlled, single-center interventional design. The aim is to investigate the&#xD;
      effects on cognitive function and cardiometabolic risk markers after 12 weeks intake of a&#xD;
      berry product vs. a reference product. The reference will be isocaloric and matched in taste,&#xD;
      appearance, volume and macronutrient composition to the active berry product.&#xD;
&#xD;
      Two groups, each of 50 volunteers, are studied. Volunteers will be patients attending the&#xD;
      Cognitive medicine unit at Ängelholm hospital, who have mild cognitive impairment (but not&#xD;
      dementia). One group of volunteers will consume the berry product while the other group act&#xD;
      as control and will consume the reference product.&#xD;
&#xD;
      Each volunteer will be seen for a screening visit as well as one pre- and one&#xD;
      post-intervention visit at the clinic. In addition, there will be 2 follow-up calls in&#xD;
      between visits. Pre- and post-intervention visits will include cognitive assessment with the&#xD;
      CANTAB battery (episodic memory and verbal recognition memory), as well as additional&#xD;
      cognitive and behavioral tests. Cardiometabolic parameters will be addressed (plasma glucose,&#xD;
      insulin, inflammatory markers, blood lipids, body composition) and fecal samples collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">March 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CANTAB - Paired Associate Learning test (PAL28)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate how daily berry intake affects cognitive function (primary objective) measured by episodic memory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Episodic memory (test verbal recognition memory (VRM) (free-, immediate- and delayed recall)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention, psychomotor speed and executive function (Trail making test (TMT) A and B)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selective attention and processing speed (Stroop color-word test)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal fluency (letter &quot;S&quot; word fluency test)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of novel words on letter &quot;S&quot; during 60 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior and quality of life (AES, Apathy evaluation score (self))</measure>
    <time_frame>12 weeks</time_frame>
    <description>Answers given by the participants on 18 questions reflect apathy including behavioral, cognitive and emotional indicators on a scale 18-72 where higher scores reflect more apathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior and quality of life (Apathy evaluation score (informant))</measure>
    <time_frame>12 weeks</time_frame>
    <description>Answers given by someone close to the participant on 18 questions reflect apathy including behavioral, cognitive and emotional indicators on a scale 18-72 where higher scores reflect more apathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimension (EQ-5D) life quality score.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Participant marks on a visual analogue scale from 0 to 100 how they value their current health status where 0 represents the lowest, and 100 highest, health status and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety Depression (HAD) Score.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Self-assessment with 14 items that assess anxiety and depression symptoms before and after the intervention on a scale from 0 to 21, with higher scores indication the presence of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in systolic blood pressure in mm/Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in diastolic blood pressure in mm/Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in bpm (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body weight index (kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body fat composition (% body fat, fat free mass (kg), basal metabolic rate (BMR) measured with TANITA scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-hip ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist circumference/hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose (mM)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Homeostasis model assessment of insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: total cholesterol mg/dl</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: LDL-cholesterol mg/dl</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: HDL-cholesterol mg/dl</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: triglycerides mg/dl</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: apolipoprotein B/ apolipoprotein A1 ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism: oxLDL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Oxidized LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function: alanine aminotransferase (ALAT) (ukat/L)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: hsCRP (mg/L)</measure>
    <time_frame>12 weeks</time_frame>
    <description>high sensitive c-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: plasma serum amyloid A (mg/L)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: IL-6 ng/L</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: TNFalfa ng/L</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: IL-12 ng/L</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: IL-15 ng/L</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: MCP-1 ng/L</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: sVCAM-1 (ukat/L)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation: IFN-g</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker related to cognitive function: BDNF</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in plasma brain-derived neurotrophic factor (BDNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAL scores (PALTEA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in PALTEA score at different levels of the test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VRM scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in VRM scores at different levels of the test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in 16s microbial composition in feces samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire describing gut function and habits to be filled out before and after the intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: correlations between primary variables (cognitive function) and secondary outcome measures and gut microbiota composition.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: analyses of interactions between effects on cognitive function and the participant characteristics; dietary habits, drugs, dementia risk-allele, education level and gender.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>safety outcomes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cognitive Impairment, Mild</condition>
  <condition>Memory Impairment</condition>
  <arm_group>
    <arm_group_label>Active berry product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily consumption over the period of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily consumption over the period of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active berry product</intervention_name>
    <description>Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.</description>
    <arm_group_label>Active berry product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference product</intervention_name>
    <description>Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.</description>
    <arm_group_label>Reference product</arm_group_label>
    <other_name>inactive control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 55 years or older.&#xD;
&#xD;
          2. Cognitive impairment in accordance with the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (DSM)-5 criteria and global deterioration scale (GDS) stage 3.&#xD;
&#xD;
          3. Capable and willing to give written informed consent.&#xD;
&#xD;
          4. Capable and willing to perform cognitive testing (mastering the Swedish language,&#xD;
             functional vision and hearing or the use of visual or hearing aids during testing).&#xD;
&#xD;
          5. Capable and willing to ingest the study beverage for 12 weeks and to follow the&#xD;
             instructions given.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MMSE (Mini-Mental State Examination) &lt;24 (at screening or in the last 3 months).&#xD;
&#xD;
          2. Cognitive disease (e.g. dementia) according to Global Deterioration Scale (GDS) stage&#xD;
             4 and up.&#xD;
&#xD;
          3. Severe affective disorder with current symptoms&#xD;
&#xD;
          4. Severe mental disorder.&#xD;
&#xD;
          5. Newly diagnosed or poorly regulated thyroid disease (unstable dose since 3 months&#xD;
             back).&#xD;
&#xD;
          6. Ongoing insulin therapy.&#xD;
&#xD;
          7. Ongoing treatment for malignancy*.&#xD;
&#xD;
          8. Conditions with major impact on the gastrointestinal tract (such as Crohn's disease,&#xD;
             ulcerative colitis, diagnosed gluten intolerance, undertaken intestinal resection or&#xD;
             weight loss surgery).&#xD;
&#xD;
          9. Planned major intervention in health care over the next 3 months (the study period).&#xD;
&#xD;
         10. Undergoing antibiotic therapy for the last 3 months prior to inclusion in the study.&#xD;
&#xD;
         11. Allergy / intolerance to berries or other ingredients in the study products (i.e.,&#xD;
             colorants, aromas, starch).&#xD;
&#xD;
         12. Vegetarians / vegans.&#xD;
&#xD;
         13. Smoking.&#xD;
&#xD;
         14. Abuse of alcohol or psychoactive substance.&#xD;
&#xD;
         15. Significant change in medication over the last 3 months.&#xD;
&#xD;
         16. Daily, regular high consumption of berries or juices / marmalade / product with high&#xD;
             content of these berries (guideline no more than 5 grams per day). (Can be recruited&#xD;
             for the study if this intake ceases before visit 1. High consumes (approximately 1 dl&#xD;
             of berries per day) has to cease with this at least one month before visit 1.)&#xD;
&#xD;
         17. Taking supplements with potential cognitive effects (e.g. omega-3, ginko biloba), or&#xD;
             containing grape and berry extracts or probiotics (capsules or other). (Can be&#xD;
             recruited if this intake ceases at least one month before visit 1).&#xD;
&#xD;
         18. Planned longer absence/vacation during the next 3 months (the study period).&#xD;
&#xD;
         19. Concurrent participation in other clinical intervention trials&#xD;
             (dietary/pharmacological).&#xD;
&#xD;
         20. Other reasons that make the Study investigator in consultation with the responsible&#xD;
             physician deem the person inappropriate to include.&#xD;
&#xD;
               -  basalioma exempt from exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Skane</investigator_affiliation>
    <investigator_full_name>Maria Landqvist Waldö</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

